



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
09/964,277	09/25/2001	Ralf M. Luche	200125.434	9940

500 7590 09/27/2005

SEED INTELLECTUAL PROPERTY LAW GROUP PLLC
701 FIFTH AVE
SUITE 6300
SEATTLE, WA 98104-7092

EXAMINER

YU, MISOOK

ART UNIT PAPER NUMBER

1642

DATE MAILED: 09/27/2005

Please find below and/or attached an Office communication concerning this application or proceeding.

Office Action Summary

Application No.

09/964,277

Applicant(s)

LUCHE ET AL.

Examiner

MISOOK YU, Ph.D.

Art Unit

1642

-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address --

Period for Reply

A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 3 MONTH(S) OR THIRTY (30) DAYS, WHICHEVER IS LONGER, FROM THE MAILING DATE OF THIS COMMUNICATION.

- Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.
- If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.
- Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133). Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).

Status

- 1) ☒ Responsive to communication(s) filed on 19 May 2005.
- 2a) ☐ This action is **FINAL**. 2b) ☒ This action is non-final.
- 3) ☐ Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under *Ex parte Quayle*, 1935 C.D. 11, 453 O.G. 213.

Disposition of Claims

- 4) ☒ Claim(s) 51 and 55-68 is/are pending in the application.
- 4a) Of the above claim(s) _____ is/are withdrawn from consideration.
- 5) ☒ Claim(s) 51 and 56 is/are allowed.
- 6) ☒ Claim(s) 55,57,58 and 63 is/are rejected.
- 7) ☐ Claim(s) _____ is/are objected to.
- 8) ☐ Claim(s) _____ are subject to restriction and/or election requirement.

Application Papers

- 9) ☐ The specification is objected to by the Examiner.
- 10) ☐ The drawing(s) filed on _____ is/are: a) ☐ accepted or b) ☐ objected to by the Examiner.
Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).
Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).
- 11) ☐ The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.

Priority under 35 U.S.C. § 119

- 12) ☐ Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).
- a) ☐ All b) ☐ Some * c) ☐ None of:
- ☐ Certified copies of the priority documents have been received.
 - ☐ Certified copies of the priority documents have been received in Application No. _____.
 - ☐ Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).

* See the attached detailed Office action for a list of the certified copies not received.

Attachment(s)

- ☐ Notice of References Cited (PTO-892)
- ☐ Notice of Draftsperson's Patent Drawing Review (PTO-948)
- ☐ Information Disclosure Statement(s) (PTO-1449 or PTO/SB/08)
Paper No(s)/Mail Date _____
- ☐ Interview Summary (PTO-413)
Paper No(s)/Mail Date. _____
- ☐ Notice of Informal Patent Application (PTO-152)
- ☒ Other: Exhibit A (5 pages).

Art Unit: 1642

DETAILED ACTION

Response to Amendment

The amendment filed on 5/19/2005 has been entered, and the finality of that action is withdrawn, and the prosecution is re-opened for the following reasons:

Claim Rejections - 35 USC § 102

The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action:

A person shall be entitled to a patent unless –

(e) the invention was described in (1) an application for patent, published under section 122(b), by another filed in the United States before the invention by the applicant for patent or (2) a patent granted on an application for patent by another filed in the United States before the invention by the applicant for patent, except that an international application filed under the treaty defined in section 351(a) shall have the effects for purposes of this subsection of an application filed in the United States only if the international application designated the United States and was published under Article 21(2) of such treaty in the English language.

Claims 55, 57, 58, and 64 are rejected under 35 U.S.C. 102(e) as being anticipated by either WO 02/10363 (IDS AM filed on 08/12/2002, priority date of 10 August 2000 to US Provisional 60/224,309) .

Claims 55, 57, 58, and 64 are drawn to an isolated polypeptide encoding a polypeptide encoded by the polynucleotide at least 90% identical to SEQ ID NO: 20, wherein the polypeptide comprises an amino acid sequence VHCLAGISRS (SEQ ID NO:16), wherein the polypeptide has phosphase activity on the activated MAP-kinase.

WO 02/10363 (US Provisional 60/224,309) discloses an isolated polypeptide encoding a polypeptide encoded by the polynucleotide at least 90% identical to the instant SEQ ID NO: 20, wherein the polypeptide comprises an amino acid sequence

Art Unit: 1642

SEQ ID NO: 16, and also teaches vector comprising the polynucleotide, and host cell comprising the vector at pages 34-38. Note the attached Exhibit A (sequence alignment).

The specification at page 12, 1st full paragraph discloses that the instant SEQ ID NO:16 is the domain that contains the active site. Since the polynucleotide sequence encoding the phosphase of the prior art contains the instant SEQ ID NO:16 as evidenced by the sequence alignment, the protein encoded by the polynucleotide of the prior art inherently has the claimed functional characteristic in view that the structure of the claimed invention and the prior art are the same.

Allowable Subject Matter

Claims 51 and 56 are allowed.


Conclusion

Any inquiry concerning this communication or earlier communications from the examiner should be directed to MISOOK YU, Ph.D. whose telephone number is 571-272-0839. The examiner can normally be reached on 8 A.M. to 5:30 P.M., every other Friday off.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Jeffrey Siew can be reached on 571-272-0787. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Art Unit: 1642

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see <http://pair-direct.uspto.gov>. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free).


MISOOK YU, Ph.D.
Examiner
Art Unit 1642

1501 CCTGCTCCGCTGCTCTGAGAGGTGAGCAGAAAAAGGAGAGCCCTCAGTCCACCTGT 1560
1421 GCCGACTCTGCTACCTCTGAGAGGAGAGCAGAAAGGCGGTGATCCGCGAGGTGCCC 1480
1561 GCGAGCTCTGCTACCTCTGAGAGGAGAGCAGAAAGGCGGTGATCCGCGAGGTGCCC 1620
1481 AGCTGCTCCAGGCTGCTGAGAGGCTGCTGCTGCTGAGAGCAGGCTGCTGCTGCTGCT 1540
1621 AGGAGTCCAGGCTGCTGAGAGGCTGCTGCTGCTGAGAGCAGGCTGCTGCTGCTGCT 1680
1541 GGGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCT 1600
1681 GGGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCT 1740
1601 CTGGATATCAAAATCAATGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCT 1660
1741 CTGGATATCAAAATCAATGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCT 1800
1661 TCATCAGAAAGATGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCT 1720
1801 TCATCAGAAAGATGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCT 1860
1721 CTATGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCT 1780
1861 CTATGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCT 1920
1781 AAGAGAGAAAGGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCT 1840
1921 AAGAGAGAAAGGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCT 1980
1841 AAGAGAGAAAGGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCT 1900
1981 AAGAGAGAAAGGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCT 2040
1901 CCACTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCT 1960
2041 CCACTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCT 2100
1961 TCCACGACGACGACGACGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCT 2020
2101 TCCACGACGACGACGACGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCT 2160
2021 GATATCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCT 2080
2161 GATATCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCT 2220
2081 GATCTCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCT 2140
2221 GATCTCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCT 2280
2141 TACAGCTGACGACGACGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCT 2200
2281 TACAGCTGACGACGACGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCT 2340
2201 AAGCCAAATGACAAAGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCT 2260
2341 AAGCCAAATGACAAAGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCT 2400
2261 CAGTTTAAACGACAAAGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCT 2320
2401 CAGTTTAAACGACAAAGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCT 2460
2321 TCAAGGAGAAAGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCT 2380
2461 TCAAGGAGAAAGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCT 2520
2381 ATTGAGTCTCTGAGAAAGAAAGCACTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCT 2440
2521 ATTGAGTCTCTGAGAAAGAAAGCACTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCT 2580
2441 TCACAAAAAATTCCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCT 2500

2581 TCACAAAAAATTCCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCT 2640
2501 AAAATGAGTCTATGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCT 2560
2641 AAAATGAGTCTATGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCT 2700
2561 TCTGCAATTTGAGAGATCAATGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCT 2620
2701 TCTGCAATTTGAGAGATCAATGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCT 2760
2621 ATCCCTCCCTGAG 2680
2761 ATCCCTCCCTGAG 2820
2681 AAAAGCAGAGTCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCT 2740
2821 AAAAGCAGAGTCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCT 2800
2741 ACTAAGAGATCTCAAAATTAATGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCT 2800
2880 ACTAAGAGATCTCAAAATTAATGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCT 2839
2801 AAGAGAGAGAGTCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCT 2860
2940 AAGAGAGAGAGTCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCT 2899
2861 AATCCAGAGAGAGATCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCT 2920
3000 AATCCAGAGAGAGATCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCT 3059
2921 GAGGAGACAGAGATCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCT 2980
3060 GAGGAGACAGAGATCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCT 3119
2981 AAGAGAGAGAGTCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCT 3040
3120 AAGAGAGAGAGTCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCT 3179
3041 GCCATTTTCTGAGGATCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCT 3100
3180 GCCATTTTCTGAGGATCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCT 3239
3101 AACTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCT 3160
3240 AACTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCT 3299
3161 CTTTATGAG 3220
3300 CTTTATGAG 3359
3221 TCAGCAATTTAGCTGAG 3280
3360 TCAGCAATTTAGCTGAG 3419
3281 AATGTTTAAATGAG 3332
3420 AATGTTTAAATGAG 3471

RESULT 4

AC090559
ID AC090559 standard; cDNA, 5450 BP.

AC AC090559

DT 19-JUN-2003 (first entry)

XX

XX

XX

KM

Polynucleotide relating to the invention SEQ ID NO: 108.
Gene; sex; antiproliferative; hepatocellular; nephrotropic; antiarthritic;
antiproliferative; cardiant; cytoskeletal; gene therapy; liver disease;
proliferative disorder; renal failure; cardiovascular disorder;
immunological disorder; arthritis; psoriasis; congenital heart defect;

PI-0198 P

<223> Incyte ID No: 7480570CB1

60/224,309

8/18/2000 filed

<400> 2

→ gaaaagaaga tgaggaggag agcgacggga cgggacgcga gcgggagcgc agccgccttc 60
 tcggctccgc ggcggcgccct cgcaagtccg ggagggcgag ggggcccag gggagacgcc 120
 gtgacaactt tegtttccct ctgaggggaat tgggaggctg gcggcccaa aagctttcag 180
 tccagtgtaa agctgttgga gcgcgggagc aaaggtaaag aatgatgtaa tgcgctggct 240
 gctccaaagc atcttttgtt gtggaatggt tattccagtc atctctttat gaatcaaagt 300
 tgaggggctg ctttgtggac ggagtccttt gcaagagcac atcaacggga aagagaaaga 360
 gacattcact tggagggctc ttgctgaaaa tgggtttaac tctccttttg ccagtcacca 420
 ccagcctgac ctcatacact tttagtacaa tggagtggtt gaggccttga gcacaccacc 480
 attacatcat cgtggcaaat taaagaaggga ggtgggaaaa gaggacttat tgttgtcatg 540
 gcccattgaga tgattggaac tcaaattggt actgagaggt tgggtggtct gctggaaagt 600
 ggaacggaaa aagtgtgtgt aattgatagc cggccatttg tggaatacaa tacatccacc 660
 attttggaag ccattaatat caactgtctc aagcttatga agcgaagggt gcaacaggag 720
 aaagtgttaa ttacagagct catccagcat tcagcgaac ataagggtga cattgattgc 780
 agtcagaagg ttgtagttaa cgatcaaaagc tcccaagatg ttgcctctct ctcttcagac 840
 tgttttctca ctgtacttct gggtaaactg gagaagagct tcaactctgt tcacctgctt 900
 gcaggtgggt ttgctgagtt ctctcgttgt ttccttggtc tctgtgaagg aaaatccact 960
 ctagtcccta cctgcatttc tcagccttgc ttacctgttg ccaacattgg gccaacccga 1020
 attcttccca atcttttatct tggctgccag cgagatgtcc tcaacaagga gctgatgcag 1080
 cagaatggga ttggttatgt gttaaatgcc agcaatacct gtccaaagcc tgactttatc 1140
 cccgagtctc atttccgtcg tgtgctgtg atgacagct tttgtgagaa aattttgccg 1200
 tgggttgaca aatcagtaga tttcattgag aaagcaaaag cctccaatgg atgtgttcta 1260
 gtgcactgtt tagctgggat ctcccgtctc gccaccatcg ctatcgccca catcatgaag 1320
 aggatggaca tgtctttaga tgaagcttac agatttgtga aagaaaaaag acctactata 1380
 tctccaaact tcaattttct gggccaactc ctggactatg agaagaagat taagaaccag 1440
 actggagcat cagggccaaa gagcaaacct aagctgtgct acctggagaa gccaaatgaa 1500
 cctgtccctg ctgtctcaga ggggtggacag aaaagcgaga cgccctcag tccacctgtt 1560
 gccgactctg ctacctcaga ggcagcagga caaaggcccg tgcattcccg cagcgtgccc 1620
 agcgtgcccc gcgtgcagcc gtcgctgtta gaggacagcc cgctggtaca ggcgctcagt 1680
 gggctgcacc tgtccgcaga caggctggaa gacagcaata agctcaagcg ttccttctct 1740
 ctggatatca aatcagtttc atattcagcc agcatggcag catccttaca tggcttctcc 1800
 tcatcagaag atgctttgga atactacaaa ccttccacta ctctggatgg gaccaacaag 1860
 ctatgccagt tctccctgtt tcaggaacta tcggagcaga ctcccgaac cagtccctgat 1920
 aaggaggaag ccagcatccc caagaagctg cagaccgcca ggccttcaga cagccagagc 1980
 aagcgattgc attcggtcag aaccagcagc agtggcaccg cccagaggte ccttttatct 2040
 ccactgcacg gaagtgggag cgtggaggac aattaccaca ccagcttcct tttcgccctt 2100
 tccaccagcc agcagcacct acgaaagctt gctggcctgg gccttaaggg ctggcactcg 2160
 gatattcttg ccccccagac ctctaccctt tccctgacca gcagctggta ttttgccaca 2220
 gagtccctac acttctactc tgccctcagcc atctacggag gcagtgccag ttactctgcc 2280
 tacagctgca gccagctgcc cacttgcgga gaccaagtct attctgtgct caggcggcag 2340
 aagccaagtg acagagctga ctgcggcgag agctggcatg aagagagccc ctttgaaaag 2400
 cagtttaaac gcagaagctg ccaaattgaa tttggagaga gcatcatgtc agagaacagg 2460
 tcacgggaag agctggggaa agtgggcagt cagtctagct tttcgggcag catggaaatc 2520
 attgaggtct cctgagaaga aagacacttg tgacttctat agacaatttt tttttcttgt 2580
 tcacaaaaaa attccctgta aatctgaaat atatatatgt acatacatat atatttttgg 2640
 aaaatggagc tatggtgtaa aagcaacagg tggatcaacc cagttgttac tctcttaaca 2700
 tctgcatttg agagatcagc taatacttct ctcaacaaaa atggaagggc agatgctagg 2760
 atccccctta gacggaggaa aaccatttta ttcagtgaat tacacatcct cttgttctta 2820
 aaaaagcaag tgtcttttgt gttggaggac aaaatcccct accattttca cgttgtgtta 2880
 ctaagagatc tcaaattatta gtctttgtcc ggacccttcc atagtacacc tttagcgtga 2940
 gactgagcca ccttgggggt caggtaggta gaccctgtta gggacagagc ctagtggtaa 3000
 atccaagaga aatgatccta tccaagctg attcacaac ccacgctcac ctgacagccg 3060
 agggacacga gcatcactct gctggacgga ccattagggg ccttgccaag gtctacctta 3120
 gagcaaaccc agtacctcag acaggaaagt cggggctttg accactacca tatctggtag 3180
 cccattttct aggcattgtg aataggtagg tagctagtca cacttttcag accaattcaa 3240
 actgtctatg cacaaaattc ccgtgggcct agatggagat aatttttttt tcttctcagc 3300
 tttatgaaga gaagggaac tgtctaggat tcagctgaac caccaggaac ctggcacaac 3360
 cacgatttaa gctaagggtt ggaggctaac gagtctacct cctcttttgt aaatcaaaga 3420
 attgtttaaa atgggattgt caatccttta aataaagatg aacttgggtt caagccaaat 3480

60226723 "091800

5-25-

PI-0198 P

```
gtgaatttat ttgggttggt agcagagcag cagcaccttc aaattctcag ccaaagcaga 3540
tgtttttgcc ctttctgctt cactgcatgg atacagttag taaaatgtaa taatatggca 3600
gaattttata ggaaacttcc tagggaggta aattatggga agattaagaa aggtacaaat 3660
tgctgaggag aagcaggaaa cctgtttcct tagtggcttt tatccccctg gcatgcatg 3720
gggctgatgt ttctatgatt gcctcagact ttcacattta ctagta 3766
```

005780" 02/92209